Analyst: Tresiba could generate revenue of DKK 17 billion
![Foto: Novo Nordisk](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article5601558.ece/ALTERNATES/schema-16_9/Flectouch_Tresiba_filling.jpg)
Novo Nordisk finally reached an all-important milestone on Friday last week, as the FDA approved the group’s newest insulin product Tresiba, as well as combination product Ryzodeq.
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Tresiba approval would mean massive boost to Novo share
For abonnenter
”Old” Novo drug to take center stage in Tresiba launch
For abonnenter
Analyst: Novo’s product is superior, but…
For abonnenter